Lindsay McNair MD, MPH, MSB

include the regulatory oversight of drug development in clinical trials, ethical issues related to human participant research and novel clinical research designs (e.g., participant compensation, expanded access, use of AI in informed consent interactions). From 2013 to 2023, Dr. McNair was the Chief Medical Officer for the WIRB-Copernicus Group (WCG) and on the Executive Committee of the WCG Institutional Review Board (IRB) where she oversaw IRB member selection and training, IRB policy development, and helped to maintain regulatory and accreditation compliance. Dr. McNair participates in Tufts CSDD’s postgraduate course, is adjunct faculty at Boston University and teaches graduate courses on the scientific design of clinical research studies. She is also an associate editor for the Journal of Empirical Research on Human Research Ethics, and is in the NYU Compassionate Use Pre-Approval Access (CUPA) Working Group. She has previously been part of the Human Subjects Review Board of the US Environmental Protection Agency (EPA HSRB), various working groups within Harvard’s Multi- Regional Clinical Trials (MRCT) program and in the Advancing Effective Research Ethics Oversight (AEREO) consortium. Dr. McNair received her medical degree from the University of Connecticut School of Medicine, and MPH and Master’s of Science in Bioethics from Boston University and Clarkson University Graduate School respectively.